BioNTech beat sales expectations for a second straight quarter as profits jumped to almost €2.8bn on soaring demand for its coronavirus vaccine.
The German biotech group said on Monday it expected its full-year revenues from the jab, developed in a joint venture with Pfizer, to be about €15.9bn, well above a previous forecast of €12.4bn.
BioNTech said that by July 21 it had signed contracts for 2.2bn doses for delivery this year and more than 1bn for 2022 and beyond, and that it expected annual manufacturing capacity to reach 3bn doses by the end of the year.
您已閱讀17%（563字），剩餘83%（2822字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。